摘要
目的 探讨仙灵骨葆胶囊联合骨肽片对骨质疏松性胸腰椎骨折手术患者术后骨代谢指标的影响。方法 选取新余银河医院2020年1月至2022年5月接受手术治疗的83例骨质疏松性胸腰椎骨折患者,根据患者入院单尾号分组,单号设对照组(42例)、双号设观察组(41例);对照组予骨肽片治疗,观察组予仙灵骨葆胶囊联合骨肽片治疗,两组均于术后当天开始服药。对比两组术后疼痛程度[视觉模拟评分法(VAS)],骨密度(BMD),骨代谢指标[骨源性碱性磷酸酶(BALP)、骨钙素(BGP)],腰椎功能[Oswestry功能障碍指数(ODI)]及不良反应。结果 治疗4个疗程后,观察组VAS评分较对照组低,BMD、BALP、BGP水平较对照组高,差异有统计学意义(P<0.05);随访6个月,观察组ODI评分较对照组低,差异有统计学意义(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论 骨质疏松性胸腰椎骨折手术患者采用仙灵骨葆胶囊联合骨肽片治疗可减轻术后疼痛,提高骨密度,改善骨代谢指标,提升腰椎功能,且安全性好。
Objective To investigate the effects of xianling gubao capsules combined with ossotide tablets on postoperative bone metabolism in patients with osteoporotic thoracolumbar fracture(OTF).Methods A total of 83 patients with OTF who received surgical treatment from January 2020 to May 2022 were selected from Xinyu Yinhe Hospital.According to the end number of admission sheets,control group(42 cases)with single number and observation group(41 cases)with even number were set up.The control group was treated with ossotide tablets,and the observation group was treated with xianling gubao capsules combined with ossotide tablets.Postoperative pain degree[visual analogue scale(VAS)],bone mineral density(BMD),bone metabolic indexes[bone-derived alkaline phosphatase(BALP),osteocalcin(BGP)],lumbar function[Oswestry Disability Index(ODI)]and adverse reactions were compared between the two groups.Results After 4 courses of treatment,VAS score of observation group was lower than control group,BMD,BALP,BGP level was higher than control group,the difference was statistically significant(P<0.05).After 6 months of follow-up,ODI score of observation group was lower than control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Xianling gubao capsules combined with ossotide tablets can reduce postoperative pain,increase bone density,improve bone metabolism index,and enhance lumbar function in patients undergoing OTF surgery,with good safety.
作者
廖宏伟
孙可生
LIAO Hongwei;SUN Kesheng(Xinyu Yinhe Hospital,Xinyu Jiangxi 338000,China)
出处
《药品评价》
CAS
2023年第9期1127-1130,共4页
Drug Evaluation
关键词
骨质疏松性骨折
脊柱骨折
胸椎
腰椎
仙灵骨葆胶囊
骨肽片
骨代谢指标
Osteoporotic fractures
Spinal fractures
Thoracic vertebrae
Lumbar vertebrae
Xianling gubao capsules
Ossotide tablets
Bone metabolism index